Featured

In wake of Binary Capital scandal, VC firms dust off sexual harassment policies

Deal terms shift toward investors

The terms they are a-changin’

Startups face new social media hurdle: politically charged online reviews

This year's hottest week in IPOs features a few venture-backed companies, including Blue Apron

Benhamou Global Ventures closes $80 mln third fund, broadens global LP base

Fund performance: IVP, Contour lead eclectic venture portfolio for NY LP

Bell Mason’s Heidi Mason on best practices for corporate venture capital

Solar eclipse: Venture investments fall further in 2017

Biotech boom continues with Repare’s $90 mln Series A, Zymeworks IPO

Canada’s life sciences sector is on a roll. Current levels of venture capital investment are unprecedented. This week another major deal was announced, with Repare Therapeutics, a Montréal developer of precision oncology drugs, securing about $90 million in a Series A financing. One of the sector’s other big stories is the IPO of biotherapeutics provider Zymeworks. The company, which last month raised about $86 million on the Toronto and New York exchanges, is now being talked about as Canada’s next biotech anchor company.